Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation

Urtica dioica modulates hippocampal insulin signaling and recognition memory deficit in streptozotocin induced diabetic mice

(2016) Sita Sharan Patel et al.   METABOLIC BRAIN DISEASE

Induction of Vascular Insulin Resistance and Endothelin-1 Expression and Acceleration of Atherosclerosis by the Overexpression of Protein Kinase C-β Isoform in the Endothelium

(2013) Qian Li et al.   CIRCULATION RESEARCH

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

(2013) Jing Li et al.   Journal of Translational Medicine

Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells

(2012) Tiziana Sinagra et al.   BIOCHEMICAL PHARMACOLOGY

Protein Kinase C-β Contributes to Impaired Endothelial Insulin Signaling in Humans With Diabetes Mellitus

(2012) Corey E. Tabit et al.   CIRCULATION

Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells

(2012) Marianna Terrasi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Rosiglitazone, a PPAR-γ agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes

(2011) R. T. Mattos et al.   INFLAMMATION RESEARCH

Rosiglitazone Attenuates Endothelial Progenitor Cell Apoptosis Induced by TNF-α via ERK/MAPK and NF-κB Signal Pathways

(2011) Shengjie Xu et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo

(2010) Craig Cherrin et al.   CANCER BIOLOGY & THERAPY

PPARγ agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cells

(2010) Noriko Ogasawara et al.   PHARMACOLOGICAL RESEARCH

Rosiglitazone inhibits high glucose-induced apoptosis in human umbilical vein endothelial cells through the PI3K/Akt/eNOS pathway

(2009) Jing Wu et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model

(2009) Michaela Luconi et al.   ENDOCRINE-RELATED CANCER

Rosiglitazone Prevents High Glucose-Induced Vascular Endothelial Growth Factor and Collagen IV Expression in Cultured Mesangial Cells

(2009) Catharine Whiteside et al.   Experimental Diabetes Research

PPARα and PPARγ attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities

(2009) Wen Huang et al.   FASEB JOURNAL

PPARγ activation in adipocytes is sufficient for systemic insulin sensitization

(2009) Shigeki Sugii et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A New Mechanism Involving ERK Contributes to Rosiglitazone Inhibition of Tumor Necrosis Factor-α and Interferon-γ Inflammatory Effects in Human Endothelial Cells

(2008) Adriana Lombardi et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature

(2008) Sheng Zhong Duan et al.   CIRCULATION RESEARCH

Keratinocyte-Derived Vascular Endothelial Growth Factor Biosynthesis Represents a Pleiotropic Side Effect of Peroxisome Proliferator-Activated Receptor-  Agonist Troglitazone but Not Rosiglitazone and Involves Activation of p38 Mitogen-Activated Protein Kinase: Implications for Diabetes-Impaired Skin Repair

(2008) D. Schiefelbein et al.   MOLECULAR PHARMACOLOGY